{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"The corneal events were graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results are presented for number of participants with any corneal events by maximum grade as per CTCAE grade.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"Up to 153 weeks","title":"DE Phase: Number of Participants With Any Corneal Event by Maximum Grade as Per CTCAE Grade","type":"SECONDARY","unitOfMeasure":"Participants"}